Tumor M2 pyruvate kinase – determination in breast cancer patients receiving trastuzumab therapy

• Published in: Cancer letters 2002-12, Vol.187 (1), p.223-228
• Main Authors: Hoopmann, Markus, Warm, Mathias, Mallmann, Peter, Thomas, Anke, Göhring, Uwe-Jochen, Schöndorf, Thomas
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - enzymology; Adult; Aged; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Antineoplastic agents; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Biomarkers; Biomarkers, Tumor - blood; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - enzymology; Cancer therapies; Chemotherapy; Clinical course; Drug therapy; Female; Humans; Medical sciences; Middle Aged; Mucin-1 - metabolism; Neoplasm Staging; Pharmacology. Drug treatments; Plasma; Prognosis; Proteins; Pyruvate Kinase - blood; Receptor, ErbB-2 - metabolism; Receptors, Estrogen - metabolism; Receptors, Progesterone - metabolism; Retrospective Studies; Trastuzumab; Treatment Outcome; Tumor M2 pyruvate kinase
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/S0304-3835(02)00404-4

This study was designed to investigate the value of tumor M2 pyruvate kinase (tumor M2-PK) determination as an early marker for response to trastuzumab therapy in patients with metastasized breast cancer. Plasma samples of 20 trastuzumab patients were collected immediately after standard hematological investigations. The tumor M2-PK level was quantified using an enzyme linked immunosorbent assay (ScheBo ® Biotech) and CA 15-3 was measured automatically using the Bayer Immuno 1™ immunoanalyzer and the corresponding assay. Each assay was performed in duplicate. The values were analyzed for correlation to the clinical course of each patient. Median observation time was 13 months with a range from 4 to 22 months. In 17/20 (85%) patients, tumor M2-PK determination was a marker for the clinical course of their disease. In this ‘tumor M2-PK sensitive’ group, 49 known clinical events (remission or progression according to UICC criteria) were recorded. The variation in tumor M2-PK level paralleled 63% of the clinical events (31/49). Our data suggest that tumor M2-PK determination in the plasma of patients with metastasized breast cancer could be a helpful tool for monitoring therapeutic success.